653 results on '"Scholl, Sebastian"'
Search Results
2. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study
3. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
4. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
5. Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia
6. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
7. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
8. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
9. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
10. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
11. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
12. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
13. Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia
14. Application of a nanoindentation-based approach for parameter identification to a crystal plasticity model for bcc metals
15. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
16. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
17. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
18. A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).
19. Primär- und Rezidivtherapie akuter Leukämien
20. Ziele und Optionen der palliativen Therapie der akuten myeloischen Leukämie
21. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
22. A comprehensive quantitative characterisation of the multiphase microstructure of a thick-section high strength steel
23. Significance of separations occurring in mechanical testing of thermomechanical rolled pipeline steels
24. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
25. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
26. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
27. Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation
28. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens
29. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed / refractory large B-cell lymphoma: findings from a German monocentric study.
30. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
31. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials
32. Numerical simulation of dual-phase steel based on real and virtual three-dimensional microstructures
33. Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients
34. Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
35. Synergistic Effects of the RAR alpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.
36. HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
37. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
38. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
39. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
40. A 19-year-old patient with atypical chronic myeloid leukemia
41. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
42. Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials
43. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.
44. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL.
45. PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
46. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
47. P474: FUNCTIONAL (PHOSPHO-)PROTEOMICS OF DRUG RESPONSE IN ACUTE MYELOID LEUKEMIA
48. S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
49. Geographien des Protests
50. 5.3 Zwischenfazit: Raum, Protestkarawanen und die Führung der Protestkommunikation der MPJD
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.